ProQR Therapeutics N.V. (NASDAQ:PRQR) announced today the closing of its initial public offering of 8,625,000 ordinary shares at a public offering price of $13.00 per share, which includes the exercise in full by the underwriters of their option to purchase 1,125,000 additional ordinary shares. The aggregate net proceeds to the Company, after underwriting discounts and commissions and other estimated offering expenses, will be approximately $102 million. The company’s ordinary shares were approved for listing on the NASDAQ Global Market and began trading under the symbol “PRQR” on September 18, 2014. ProQR Therapeutics N.V. (NASDAQ:PRQR) belongs to Healthcare sector. Its weekly performance is -5.70%. On last trading day company shares ended up $16.21. ProQR Therapeutics N.V. (NASDAQ:PRQR) distance from 50-day simple moving average (SMA50) is 0.06%.

Array BioPharma (Nasdaq: ARRY) presented final results from a Phase II trial of binimetinib in patients with advanced NRAS mutant melanoma. Array BioPharma, Inc. (NASDAQ:ARRY) shares fell -6.88% in last trading session and ended the day at $3.25. ARRY Gross Margin is -9.30% and its return on assets is -59.50%. Array BioPharma, Inc. (NASDAQ:ARRY) quarterly performance is -20.73%.

Brooks Automation (NASDAQ:BRKS) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.02. The company had revenue of $117.35 million for the quarter, compared to the consensus estimate of $116.90 million. During the same quarter in the previous year, the company posted $0.10 earnings per share. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. Analysts expect that Brooks Automation will post $0.27 EPS for the current fiscal year. On 07 October, Brooks Automation, Inc. (NASDAQ:BRKS) shares fell -1.81% and was closed at $10.30. BRKS EPS growth in last 5 year was 61.80%. Brooks Automation, Inc. (NASDAQ:BRKS) year to date (YTD) performance is 0.68%.

Zacks restated their neutral rating on shares ofTaubman Centers (NYSE:TCO) in a report issued on Thursday. They currently have a $77.00 target price on the stock. Taubman Centers, Inc. (NYSE:TCO) ended the last trading day at $72.80. Company weekly volatility is calculated as 1.29% and price to cash ratio as 34.82. Taubman Centers, Inc. (NYSE:TCO) showed a weekly performance of -0.19%.

Geron Corporation (NASDAQ:GERN) on Aug. 11 reported financial results for the second quarter ended June 30, 2014. For the second quarter of 2014, the company reported a net loss of $8.7 million, or $0.06 per share, compared to $8.9 million, or $0.07 per share, for the comparable 2013 period. Revenues for the second quarter of 2014 were $341,000 compared to $112,000 for the comparable 2013 period. Interest and other income for the second quarter of 2014 amounted to $99,000 compared to $56,000 for the comparable 2013 period. Geron Corporation (NASDAQ:GERN) shares fell -5.45% in last trading session and ended the day at $1.91. GERN return on assets is -31.50%. Geron Corporation (NASDAQ:GERN) quarterly performance is -34.81%.